Literature DB >> 25483077

Tumor-targeting Salmonella typhimurium A1-R decoys quiescent cancer cells to cycle as visualized by FUCCI imaging and become sensitive to chemotherapy.

Shuya Yano1, Yong Zhang, Ming Zhao, Yukihiko Hiroshima, Shinji Miwa, Fuminari Uehara, Hiroyuki Kishimoto, Hiroshi Tazawa, Michael Bouvet, Toshiyoshi Fujiwara, Robert M Hoffman.   

Abstract

Quiescent cancer cells are resistant to cytotoxic agents which target only proliferating cancer cells. Time-lapse imaging demonstrated that tumor-targeting Salmonella typhimurium A1-R (A1-R) decoyed cancer cells in monolayer culture and in tumor spheres to cycle from G0/G1 to S/G2/M, as demonstrated by fluorescence ubiquitination-based cell cycle indicator (FUCCI) imaging. A1-R infection of FUCCI-expressing subcutaneous tumors growing in nude mice also decoyed quiescent cancer cells, which were the majority of the cells in the tumors, to cycle from G0/G1 to S/G2/M, thereby making them sensitive to cytotoxic agents. The combination of A1-R and cisplatinum or paclitaxel reduced tumor size compared with A1-R monotherapy or cisplatinum or paclitaxel alone. The results of this study demonstrate that A1-R can decoy quiescent cancer cells to cycle to S/G2/M and sensitize them to cytotoxic chemotherapy. These results suggest a new paradigm of bacterial-decoy chemotherapy of cancer.

Entities:  

Keywords:  FUCCI; GFP, RFP, imaging; S. typhimurium A1-R; Salmonella typhimurium; cell cycle; chemotherapy; decoy; fluorescence ubiquitination-based cell cycle indicator; S. typhimurium; tumor-targeting bacteria

Mesh:

Substances:

Year:  2014        PMID: 25483077      PMCID: PMC4615054          DOI: 10.4161/15384101.2014.964115

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  33 in total

1.  Antagonistic drug combinations that select against drug resistance: from bacteria to cancer.

Authors:  Mikhail V Blagosklonny
Journal:  Cancer Biol Ther       Date:  2007-07       Impact factor: 4.742

Review 2.  "Targeting the absence" and therapeutic engineering for cancer therapy.

Authors:  Mikhail V Blagosklonny
Journal:  Cell Cycle       Date:  2008-05-08       Impact factor: 4.534

Review 3.  How cancer could be cured by 2015.

Authors:  Mikhail V Blagosklonny
Journal:  Cell Cycle       Date:  2005-02-21       Impact factor: 4.534

4.  Tumor-targeting bacterial therapy with amino acid auxotrophs of GFP-expressing Salmonella typhimurium.

Authors:  Ming Zhao; Meng Yang; Xiao-Ming Li; Ping Jiang; Eugene Baranov; Shukuan Li; Mingxu Xu; Sheldon Penman; Robert M Hoffman
Journal:  Proc Natl Acad Sci U S A       Date:  2005-01-11       Impact factor: 11.205

Review 5.  Cancer stem cell and cancer stemloids: from biology to therapy.

Authors:  Mikhail V Blagosklonny
Journal:  Cancer Biol Ther       Date:  2007-10-10       Impact factor: 4.742

6.  Systemic targeting of primary bone tumor and lung metastasis of high-grade osteosarcoma in nude mice with a tumor-selective strain of Salmonella typhimurium.

Authors:  Katsuhiro Hayashi; Ming Zhao; Kensuke Yamauchi; Norio Yamamoto; Hiroyuki Tsuchiya; Katsuro Tomita; Hiroyuki Kishimoto; Michael Bouvet; Robert M Hoffman
Journal:  Cell Cycle       Date:  2009-03-20       Impact factor: 4.534

7.  Visualizing spatiotemporal dynamics of multicellular cell-cycle progression.

Authors:  Asako Sakaue-Sawano; Hiroshi Kurokawa; Toshifumi Morimura; Aki Hanyu; Hiroshi Hama; Hatsuki Osawa; Saori Kashiwagi; Kiyoko Fukami; Takaki Miyata; Hiroyuki Miyoshi; Takeshi Imamura; Masaharu Ogawa; Hisao Masai; Atsushi Miyawaki
Journal:  Cell       Date:  2008-02-08       Impact factor: 41.582

8.  Efficacy of a genetically-modified Salmonella typhimurium in an orthotopic human pancreatic cancer in nude mice.

Authors:  Chisa Nagakura; Katsuhiro Hayashi; Ming Zhao; Kensuke Yamauchi; Norio Yamamoto; Hiroyuki Tsuchiya; Katsuro Tomita; Michael Bouvet; Robert M Hoffman
Journal:  Anticancer Res       Date:  2009-06       Impact factor: 2.480

9.  Monotherapy with a tumor-targeting mutant of Salmonella typhimurium cures orthotopic metastatic mouse models of human prostate cancer.

Authors:  Ming Zhao; Jack Geller; Huaiyu Ma; Meng Yang; Sheldon Penman; Robert M Hoffman
Journal:  Proc Natl Acad Sci U S A       Date:  2007-06-04       Impact factor: 11.205

10.  Cancer metastasis directly eradicated by targeted therapy with a modified Salmonella typhimurium.

Authors:  Katsuhiro Hayashi; Ming Zhao; Kensuke Yamauchi; Norio Yamamoto; Hiroyuki Tsuchiya; Katsuro Tomita; Robert M Hoffman
Journal:  J Cell Biochem       Date:  2009-04-15       Impact factor: 4.429

View more
  57 in total

Review 1.  Tumour-targeting bacteria engineered to fight cancer.

Authors:  Shibin Zhou; Claudia Gravekamp; David Bermudes; Ke Liu
Journal:  Nat Rev Cancer       Date:  2018-12       Impact factor: 60.716

2.  Improved micro-distribution of antibody-photon absorber conjugates after initial near infrared photoimmunotherapy (NIR-PIT).

Authors:  Tadanobu Nagaya; Yuko Nakamura; Kazuhide Sato; Toshiko Harada; Peter L Choyke; Hisataka Kobayashi
Journal:  J Control Release       Date:  2016-04-05       Impact factor: 9.776

3.  Heterogeneous cell-cycle behavior in response to UVB irradiation by a population of single cancer cells visualized by time-lapse FUCCI imaging.

Authors:  Shinji Miwa; Shuya Yano; Hiroaki Kimura; Mako Yamamoto; Makoto Toneri; Takashi Murakami; Katsuhiro Hayashi; Norio Yamamoto; Toshiyoshi Fujiwara; Hiroyuki Tsuchiya; Robert M Hoffman
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

4.  Engineered bacteria detect spatial profiles in glucose concentration within solid tumor cell masses.

Authors:  Jan T Panteli; Neil S Forbes
Journal:  Biotechnol Bioeng       Date:  2016-09-20       Impact factor: 4.530

5.  Salmonella typhimurium A1-R targeting of a chemotherapy-resistant BRAF-V600E melanoma in a patient-derived orthotopic xenograft (PDOX) model is enhanced in combination with either vemurafenib or temozolomide.

Authors:  Kei Kawaguchi; Kentaro Igarashi; Takashi Murakami; Tasuku Kiyuna; Ming Zhao; Yong Zhang; Scott D Nelson; Tara A Russell; Sarah M Dry; Arun S Singh; Bartosz Chmielowski; Yunfeng Li; Michiaki Unno; Fritz C Eilber; Robert M Hoffman
Journal:  Cell Cycle       Date:  2017-06-16       Impact factor: 4.534

6.  Tumor-specific cell-cycle decoy by Salmonella typhimurium A1-R combined with tumor-selective cell-cycle trap by methioninase overcome tumor intrinsic chemoresistance as visualized by FUCCI imaging.

Authors:  Shuya Yano; Kiyoto Takehara; Ming Zhao; Yuying Tan; Qinghong Han; Shukuan Li; Michael Bouvet; Toshiyoshi Fujiwara; Robert M Hoffman
Journal:  Cell Cycle       Date:  2016-05-06       Impact factor: 4.534

7.  Intra-arterial administration of tumor-targeting Salmonella typhimurium A1-R regresses a cisplatin-resistant relapsed osteosarcoma in a patient-derived orthotopic xenograft (PDOX) mouse model.

Authors:  Kentaro Igarashi; Kei Kawaguchi; Takashi Murakami; Tasuku Kiyuna; Kentaro Miyake; Scott D Nelson; Sarah M Dry; Yunfeng Li; Jane Yanagawa; Tara A Russell; Arun S Singh; Norio Yamamoto; Katsuhiro Hayashi; Hiroaki Kimura; Shinji Miwa; Hiroyuki Tsuchiya; Fritz C Eilber; Robert M Hoffman
Journal:  Cell Cycle       Date:  2017-05-11       Impact factor: 4.534

Review 8.  A "Double-Edged" Scaffold: Antitumor Power within the Antibacterial Quinolone.

Authors:  Gregory S Bisacchi; Michael R Hale
Journal:  Curr Med Chem       Date:  2016       Impact factor: 4.530

9.  The irony of highly-effective bacterial therapy of a patient-derived orthotopic xenograft (PDOX) model of Ewing's sarcoma, which was blocked by Ewing himself 80 years ago.

Authors:  Takashi Murakami; Tasuku Kiyuna; Kei Kawaguchi; Kentaro Igarashi; Arun S Singh; Yukihiko Hiroshima; Yong Zhang; Ming Zhao; Kentaro Miyake; Scott D Nelson; Sarah M Dry; Yunfeng Li; Jonathan C DeLong; Thinzar M Lwin; Takashi Chishima; Kuniya Tanaka; Michael Bouvet; Itaru Endo; Fritz C Eilber; Robert M Hoffman
Journal:  Cell Cycle       Date:  2017-03-15       Impact factor: 4.534

10.  Tumor-targeting Salmonella typhimurium A1-R combined with recombinant methioninase and cisplatinum eradicates an osteosarcoma cisplatinum-resistant lung metastasis in a patient-derived orthotopic xenograft (PDOX) mouse model: decoy, trap and kill chemotherapy moves toward the clinic.

Authors:  Kentaro Igarashi; Kei Kawaguchi; Tasuku Kiyuna; Kentaro Miyake; Masuyo Miyake; Shukuan Li; Qinghong Han; Yuying Tan; Ming Zhao; Yunfeng Li; Scott D Nelson; Sarah M Dry; Arun S Singh; Irmina A Elliott; Tara A Russell; Mark A Eckardt; Norio Yamamoto; Katsuhiro Hayashi; Hiroaki Kimura; Shinji Miwa; Hiroyuki Tsuchiya; Fritz C Eilber; Robert M Hoffman
Journal:  Cell Cycle       Date:  2018-04-10       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.